122 related articles for article (PubMed ID: 20484617)
1. Dose-related reduction in bupropion plasma concentrations by ritonavir.
Park J; Vousden M; Brittain C; McConn DJ; Iavarone L; Ascher J; Sutherland SM; Muir KT
J Clin Pharmacol; 2010 Oct; 50(10):1180-7. PubMed ID: 20484617
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.
Hogeland GW; Swindells S; McNabb JC; Kashuba AD; Yee GC; Lindley CM
Clin Pharmacol Ther; 2007 Jan; 81(1):69-75. PubMed ID: 17186001
[TBL] [Abstract][Full Text] [Related]
3. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
4. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers.
Hesse LM; Greenblatt DJ; von Moltke LL; Court MH
J Clin Pharmacol; 2006 May; 46(5):567-76. PubMed ID: 16638740
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between ritonavir and clarithromycin.
Ouellet D; Hsu A; Granneman GR; Carlson G; Cavanaugh J; Guenther H; Leonard JM
Clin Pharmacol Ther; 1998 Oct; 64(4):355-62. PubMed ID: 9797791
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
9. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
[TBL] [Abstract][Full Text] [Related]
10. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers.
Lei HP; Yu XY; Xie HT; Li HH; Fan L; Dai LL; Chen Y; Zhou HH
Xenobiotica; 2010 Apr; 40(4):275-81. PubMed ID: 20102294
[TBL] [Abstract][Full Text] [Related]
11. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
12. Low-dose ritonavir moderately enhances nelfinavir exposure.
Kurowski M; Kaeser B; Sawyer A; Popescu M; Mrozikiewicz A
Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
[TBL] [Abstract][Full Text] [Related]
13. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Wire MB; Ballow CH; Borland J; Shelton MJ; Lou Y; Yuen G; Lin J; Lewis EW
Antimicrob Agents Chemother; 2007 Aug; 51(8):2982-4. PubMed ID: 17517848
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
15. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
[TBL] [Abstract][Full Text] [Related]
16. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM
Clin Pharmacol Ther; 2004 Apr; 75(4):310-23. PubMed ID: 15060509
[TBL] [Abstract][Full Text] [Related]
17. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
Sekar V; Kestens D; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Lefebvre E; Hoetelmans RM
J Clin Pharmacol; 2007 Apr; 47(4):479-84. PubMed ID: 17389557
[TBL] [Abstract][Full Text] [Related]
18. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
Bittner B; Riek M; Holmes B; Grange S
Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
Justesen US; Andersen AB; Klitgaard NA; Brøsen K; Gerstoft J; Pedersen C
Clin Infect Dis; 2004 Feb; 38(3):426-9. PubMed ID: 14727216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
